If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
While interest in the study of mummies dates as far back as Ptolemaic Greece, most structured scientific study began at the beginning of the 20th century. Prior to this, many rediscovered mummies were sold as curiosities or for use in pseudoscientific novelties such as mummia. The first modern scientific examinations of mummies began in 1901, conducted by professors at the English-language Government School of Medicine in Cairo, Egypt. The first X-ray of a mummy came in 1903, when professors Grafton Elliot Smith and Howard Carter used the only X-ray machine in Cairo at the time to examine the mummified body of Thutmose IV. British chemist Alfred Lucas applied chemical analyses to Egyptian mummies during this same period, which returned many results about the types of substances used in embalming. Lucas also made significant contributions to the analysis of Tutankhamun in 1922. Pathological study of mummies saw varying levels of popularity throughout the 20th century. In 1992, the First World Congress on Mummy Studies was held in Puerto de la Cruz on Tenerife in the Canary Islands. More than 300 scientists attended the Congress to share nearly 100 years of collected data on mummies. The information presented at the meeting triggered a new surge of interest in the subject, with one of the major results being the integration of biomedical and bioarchaeological information on mummies with existing databases. This was not possible prior to the Congress due to the unique and highly specialized techniques required to gather such data.
low glucose levels elevated insulin levels elevated C-peptide levels If available, a proinsulin level might be useful, as well. Other blood tests may help rule out other conditions which can cause hypoglycemia.
In mid-1943 the Australian War Cabinet decided to produce penicillin in Australia. Colonel E. V. Keogh, the Australian Army's Director of Hygiene and Pathology, was placed in charge of the effort. Keogh summoned Captain Percival Bazeley, with whom he had worked at the Commonwealth Serum Laboratories (CSL) before the war, and Lieutenant H. H. Kretchmar, a chemist, and directed them to establish a production facility by Christmas. They set off on a fact-finding mission to the United States, where they visited NRRL and obtained penicillin cultures from Coghill. They also inspected the Pfizer plant in New York and the Merck plant at Rahway, New Jersey. A production plant was established at the CSL facilities in Parkville, Victoria, and the first Australian-made penicillin began reaching the troops in New Guinea in December 1943. By 1944, CSL was producing 400 million Oxford units per week (enough for 400 treatments), and there was sufficient penicillin production to allocate some for civilian use. Wartime production in Australia was in bottles and flasks, but Bazeley made a second tour of facilities in the United States between September 1944 and March 1945 and was impressed by the progress made on deep submergence technology. In 1946 and 1947 he created a pilot deep submerged plant at CSL using small 45-litre (10 imp gal) tanks to gain experience with the technique. Two 23,000-litre (5,000 imp gal) tanks became operational in 1948, followed by eight more, giving CSL a capacity of 230,000 litres (50,000 imp gal) .
=== PDF generation === ColdFusion can generate PDF documents using standard HTML (i.e. no additional coding is needed to generate documents for print). CFML authors place HTML and CSS within a pair of cfdocument tags (or new in ColdFusion 11, cfhtmltopdf tags). The generated document can then either be saved to disk or sent to the client's browser. ColdFusion 8 introduced also the cfpdf tag to allow for control over PDF documents including PDF forms, and merging of PDFs. These tags however do not use Adobe's PDF engine but cfdocument uses a combination of the commercial JPedal Java PDF library and the free and open source Java library iText. The library used by cfhtmltopdf since cf11 has been an embedded WebKit IMPLEMENTATION. Since cf2023, Adobe has licensed PDFReactor to be the default engine underlying cfhtmltopdf.
=== Proteasomal ligases === While Ubp6 and UCH37 can remodel the ubiquitin code on a substrate by removing Ubiquitins, Ubiquitin ligases can also associate with the proteasome and attach ubiquitins. For the 26S, this includes Hul5 in yeast (or UBE3C in humans) and UBE3A/E6AP in humans. Hul5 was first identified in yeast as a 26S associated ligase along with Ubp6 and they were proposed to remodel ubiquitin chains at the proteasome. Biochemical studies show that Hul5 can attach additional ubiquitins onto a ubiquitinated substrate effectively acting as an Ubiquitin ligase. Hul5 has been proposed to bind Rpn2 in yeast, however this interaction has not been shown structurally. Further work needs to be done to understand how Hul5 works and what substrates are processed by Hul5. UBE3A/E6AP binds the C-terminus of Rpn10 in mammals. NMR has shown that a previously described disordered region of Rpn10 becomes order upon binding E6AP forming a tight interaction in the low nanomolar range.
Sources: en.wikipedia.org
electronegativity (χ) A chemical property that describes the tendency of an atom to attract a shared pair of electrons (or electron density) towards itself. An atom's electronegativity is affected both by its nuclear charge (which is proportional to the number of protons in its nucleus) and the number and location of the electrons present in its atomic shells (which influences the distance of the nucleus from the valence electrons). The higher an atom or substituent's electronegativity, the more it attracts electrons towards itself. As it is usually calculated, electronegativity is not a property of an atom alone but rather of an atom within a molecule; it therefore varies with an element's chemical environment, though it is generally considered a transferable property.
=== May === 3 May – Astronomers from the University of Warwick report 118 new confirmed exoplanets, with a further 2,000 "high-quality" candidates, detected using machine learning applied to data from NASA's Transiting Exoplanet Survey Satellite (TESS). 4 May The discovery of a thin atmosphere on the trans-Neptunian object (612533) 2002 XV93 is announced. A study published in Communications Sustainability finds that utility-scale solar power and wind power generally provide greater climate and public health benefits per dollar than direct air capture (DAC), based on modelling across 22 U.S. grid regions through 2050. The authors conclude that DAC becomes competitive mainly under a breakthrough scenario in which energy use falls from 5,500 to 800 kWh and cost from US$1,000 to US$100 per tonne of CO2 captured. A meta-analysis of over 20,000 participants concludes that drugs targeting amyloid beta peptides do not meaningfully slow progression of Alzheimer's disease. 6 May – A study in npj Space Exploration, using radar data from India's Chandrayaan-2 orbiter, reports strong evidence for subsurface water ice in four doubly-shadowed craters near the lunar south pole. 8 May – A study published in Aging Cell reports that the exceptional-longevity-associated APOE ε2 allele is associated with enhanced DNA-damage response and repair pathways in human neurons.
As Canadian pathology society did not have a registry, interested Canadian medical technologists sat for the Amereican ASCP MT certification instead. In 1939, the BOR publishes the first book outlining the educational curriculum for medical technologists entitled Curriculum for Schools of Medical Technology. In 1940, as other organizations began using the same designations, the initials MT(ASCP) were used. In 1944, due to travel wartime restrictions from World War II, the practical component of the certification was discontinued. In 1948, the written essay portion of the certification was deemed too cumbersome to assess, and the certification was switched to a multiple choice and true-false assessment that could be graded on a machine and provide exam statistics. In 1949, the BOR changed the exam format to a 200 multiple choice question exam as the multiple choice questions were found to be a more reliable indicator than true-false questions. In 1949, the BOR also created the Board of Schools (BOS) for registering schools. In 1958, BoR and ASMT assisted with the reclassification of medical technologists, putting them at the professional level in the Civil Service and allowing medical technologists to gain commission status in the US military. In 1962, the BoR began requiring 3 years of college for the MT certification. In 1972, the BoR began requiring a Bachelor's degree for the MT certification. There were 100,000 certificates issued by 1975, 200,000 by 1980, 300,000 by 1991, 400,000 by 2005, and 500,000 by 2014.
=== β1-selective agents === β1-selective beta blockers are also known as cardioselective beta blockers. Pharmacologically, the beta-blockade of the β1 receptors in the heart will act on cAMP. The function of cAMP as a second messenger in the cardiac cell is that it phosphorylates the LTCC and the ryanodine receptor to increase intracellular calcium levels and cause contraction. Beta-blockade of the β1 receptor will inhibit cAMP from phosphorylating, and it will decrease the ionotrophic and chronotropic effect. Note that drugs may be cardioselective, or act on β1 receptors in the heart only, but still have intrinsic sympathomimetic activity.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.